The Krishnamurthy-Vashisht synthetic liver went into clinical practice in 2032. By 2034, it was the standard of care in four countries and the preferred option in forty-three percent of liver transplant cases in India, because the vascular adaptation algorithm had produced outcomes that were, in a meaningful clinical sense, better than the natural organ in patients over fifty-five.
The premium programme for authentic organs still existed. There would always be people who wanted the certificate of provenance, who would pay for the idea of a thing even after the thing's practical superiority had been eroded. Priya had stopped expecting the demand to disappear. She had stopped fighting the demand and focused on the supply side — on making the supply side something that could not operate in the dark.
The Provenance Service had been the product of a specific darkness: the gap between what synthetics could do and what natural organs could do, the gap between what a family in a settlement needed and what a family of industrialists wanted, and the gap between what the legal system knew and what it could act on quickly enough to matter. All three gaps were smaller now. The first because of research. The second because of law and because of Sunita, who was on the national advisory committee. The third because of Nalini, whose story had produced a national review, and because of the community health network that Raju's group had built — people keeping count, filing reports, making the accounting available.
Suresh Paritosh had been convicted in 2031. He lived in a large house in Juhu. His kidney — the one received at Kalyani in 2025, the one that had started Nalini's investigation — functioned perfectly. He lived with it every day. She thought about this sometimes, and tried to think about it with the detachment of a doctor rather than the feeling of everything else, and did not entirely succeed.
She was at Sion Hospital on a Tuesday when she received a message from Krishnamurthy: Phase three trials complete. Full approval recommended. Press release going out tomorrow. Congratulations, Dr. Vashisht. We closed the gap.
She read the message standing in the corridor outside Room 4, where a seventeen-year-old boy was waiting for a kidney transplant — a synthetic, the new model, the one with the irregular vascular tree and the one-point-two percent rejection rate that was lower than nature's own.
She read the message twice. Then she put the phone in her pocket and knocked on Room 4 and went in.
